This atlas is the offspring of the “The National Cancer Institute (NCI) Thyroid Fine Needle Aspiration (FNA) State of the Science Conference,” hosted by the NCI and organized by Dr. Andrea Abati. Preparations for the conference began 18 months earlier with the designation of a steering committee and the establishment of a dedicated, p- manent web site. The meeting took place on October 22 and 23, 2007 in Bethesda, Maryland and was co-moderated by Susan J. Mandel and Edmund S. Cibas. The discussions and conclusions regarding terminology and morphologic criteria 1, 2 from the meeting were summarized in publications by Baloch et al. and form the framework for this atlas. The atlas is organized by the general categories of “Nondiagnostic,” “Benign,” “Follicular Neoplasm/Suspicious for a Follicular Neoplasm”, “Suspicious for Malignancy,” and “Malignant,” and it includes the defi- tions and morphologic criteria of these categories as set forth by Baloch et al. The majority of the conference participants also agreed on a category of “undetermined significance,” which is incorporated in this atlas (Chap. 4). It is critical that the cytopathologist communicate thyroid FNA interpretations to the referring physician in terms that are succinct, unambiguous, and helpful clinically. We recognize that the terminology used here is a flexible framework that can be modified by individual laboratories to meet the needs of their providers and the patients they serve.

Thyroid fine needle aspiration is one of the most commonly performed cytologic procedures and is the standard diagnostic method for managing the patient with a thyroid nodule. Until now, there has been no uniform system for reporting the results of thyroid fine needle aspiration (FNA) in the U.S. The terminology described in this book is an important advance in the field of cytopathology. It represents the results of the multidisciplinary National Cancer Institute Thyroid Fine Needle Aspiration State of The Science Conference, held in Bethesda, MD in October, 2007. The Bethesda System for Reporting Thyroid Cytopathology will provide the reader with a unified approach to diagnosing and reporting thyroid FNA interpretations. It will serve as a reference guide not just for pathologists, but also endocrinologists, surgeons, and radiologists.

This atlas is the offspring of the “The National Cancer Institute (NCI) Thyroid Fine Needle Aspiration (FNA) State of the Science Conference,” hosted by the NCI and organized by Dr. Andrea Abati. Preparations for the conference began 18 months earlier with the designation of a steering committee and the establishment of a dedicated, p- manent web site. The meeting took place on October 22 and 23, 2007 in Bethesda, Maryland and was co-moderated by Susan J. Mandel and Edmund S. Cibas. The discussions and conclusions regarding terminology and morphologic criteria 1, 2 from the meeting were summarized in publications by Baloch et al. and form the framework for this atlas. The atlas is organized by the general categories of “Nondiagnostic,” “Benign,” “Follicular Neoplasm/Suspicious for a Follicular Neoplasm”, “Suspicious for Malignancy,” and “Malignant,” and it includes the defi- tions and morphologic criteria of these categories as set forth by Baloch et al. The majority of the conference participants also agreed on a category of “undetermined significance,” which is incorporated in this atlas (Chap. 4). It is critical that the cytopathologist communicate thyroid FNA interpretations to the referring physician in terms that are succinct, unambiguous, and helpful clinically. We recognize that the terminology used here is a flexible framework that can be modified by individual laboratories to meet the needs of their providers and the patients they serve.

The previous edition of The Bethesda System for Reporting Thyroid Cytopathology provided important updates and advances in the practice of thyroid cytopathology. It was inspired by new developments in the field of thyroid cytopathology since the publication of the first edition in 2010. These included revised clinical guidelines for the management of patients with thyroid nodules, the introduction of molecular testing as an adjunct to cytopathologic examination, and the reclassification of the non-invasive follicular variant of papillary thyroid carcinoma as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). This new third edition provides updates to the current reporting terminology and diagnostic criteria, including new information on ancillary molecular testing, as well as imaging findings and clinical management. This book provides a more unified approach to diagnosing and reporting thyroid FNA interpretations. It simplifies the reporting structure by settling on just one name for each of the six categories and aligning terminology with the most recent classification of thyroid tumors by the World Health Organization. Written by experts in the field, The Bethesda System for Reporting Thyroid Cytopathology, Third Edition aims to inspire advances in thyroid cytopathologic diagnosis and the betterment of patients with thyroid nodular disease. It serves as a reference guide not just for pathologists, but also endocrinologists, surgeons, and radiologists.

This book offers clear, up-to-date guidance on how to report cytologic findings in cervical, vaginal and anal samples in accordance with the 2014 Bethesda System Update. The new edition has been expanded and revised to take into account the advances and experience of the past decade. A new chapter has been added, the terminology and text have been updated, and various terminological and morphologic questions have been clarified. In addition, new images are included that reflect the experience gained with liquid-based cytology since the publication of the last edition in 2004. Among more than 300 images, some represent classic examples of an entity while others illustrate interpretative dilemmas, borderline cytomorphologic features or mimics of epithelial abnormalities. The Bethesda System for Reporting Cervical Cytology, with its user-friendly format, is a “must have” for pathologists, cytopathologists, pathology residents, cytotechnologists, and clinicians.

This illustrated volume serves as a handy guide to diagnostic fine needle aspiration (FNA) cytology of thyroid on liquid-based preparations (LBP). It is intended to be a ready resource to accurately diagnose thyroid lesions on LBP using key cytomorphologic features. Key cytologic differential diagnosis, gross, and histopathological correlations accompany the cytological findings. The Atlas of Thyroid Cytopathology on Liquid-Based Preparations is lavishly illustrated with color images of various thyroid diseases that should familiarize pathologists with the differences between conventional smears and LBP, and between the two commonly used LBPs. Authored by leaders in the field, this atlas provides clear, concise, and practical guidance pertaining to cytomorphology and the implications of thyroid FNA diagnoses for patient care in this era of precision medicine.

This book offers a comprehensive guide to thyroid fine needle aspiration (FNA) cytology. Borderline/precursor tumors, which were introduced in the 4th edition of the WHO classification of thyroid tumors, are also incorporated. In this second edition, prominent international experts discuss the different approaches to thyroid FNA cytology employed in various countries such as Australia, Canada, China, Korea, Portugal, Switzerland, Taiwan, Thailand, Turkey, Ukraine, the USA, UK, Italy and Japan. The book not only covers key principles of thyroid cytopathology but also addresses technical aspects such as procedural complications, liquid-based cytology, immunocytochemistry, staining procedures, and potential pitfalls. Case-based descriptions and clinical findings, radiologic imaging, cytology, and histopathologic diagnosis – all complemented by a wealth of detailed photographs – will help reader understand and overcome many common dilemmas in daily practice. As such, the book represents an indispensable reference work for all cytopathologists, especially those practicing thyroid cytopathology.